U.S. Antibiotic Resistance Market (2025 - 2030) Size, Share, & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Disease
                        1.2.2. Pathogen
                        1.2.3. Drug Class
                        1.2.4. Mechanism of Action
                        1.2.5. Distribution Channel
                        1.2.6. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Disease outlook
                        2.2.2. Pathogen outlook
                        2.2.3. Drug Class outlook
                        2.2.4. Mechanism of Action
                        2.2.5. Distribution Channel
                    2.3. Competitive Insights
Chapter 3. U.S. Antibiotic Resistance Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                        3.2.2. Market restraint analysis
Chapter 4. U.S. Antibiotic Resistance Market Analysis Tools
                    4.1. Industry Analysis - Porter’s
                        4.1.1. Supplier power
                        4.1.2. Buyer power
                        4.1.3. Substitution threat
                        4.1.4. Threat of new entrant
                        4.1.5. Competitive rivalry
                    4.2. PESTEL Analysis
                        4.2.1. Political landscape
                        4.2.2. Technological landscape
                        4.2.3. Economic landscape
                    4.3. U.S. Antibiotic Resistance Market: Pipeline Analysis
Chapter 5. U.S. Antibiotic Resistance Market: Disease Estimates & Trend Analysis
                    5.1. Disease Segment Dashboard
                    5.2. U.S. Antibiotic Resistance Market: Disease Movement Analysis
                    5.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
                    5.4. cUTI
                        5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    5.5. CDI
                        5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    5.6. ABSSSI
                        5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    5.7. HABP
                        5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    5.8. CABP
                        5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    5.9. cIAI
                        5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    5.10. BSI
                        5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis
                    6.1. Pathogen Segment Dashboard
                    6.2. U.S. Antibiotic Resistance Market: Pathogen Movement Analysis
                    6.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
                    6.4. E. coli
                        6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    6.5. klebsiella pneumoniae
                        6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    6.6. P. aeruginosa
                        6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    6.7. S. aureus
                        6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    6.8. A. baumannii
                        6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    6.9. Strep. Pneumoniae
                        6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    6.10. H. influenzae
                        6.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    6.11. CDI
                        6.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    6.12. Enterococcus fecium
                        6.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis
                    7.1. Drug Class Segment Dashboard
                    7.2. U.S. Antibiotic Resistance Market: Drug Class Movement Analysis
                    7.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
                    7.4. Oxazolidinones
                        7.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
                    7.5. Lipoglycopeptides
                        7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    7.6. Tetracyclines
                        7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    7.7. Combination therapies
                        7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    7.8. Cephalosporins
                        7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    7.9. Others
                        7.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis
                    8.1. Mechanism of Action Segment Dashboard
                    8.2. U.S. Antibiotic Resistance Market: Mechanism of Action Movement Analysis
                    8.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
                    8.4. Protein Synthesis Inhibitors
                        8.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
                    8.5. Cell Wall Synthesis Inhibitors
                        8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    8.6. RNA Synthesis Inhibitors
                        8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    8.7. DNA Synthesis Inhibitors
                        8.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    8.8. Others
                        8.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. U.S. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis
                    9.1. Distribution Channel Segment Dashboard
                    9.2. U.S. Antibiotic Resistance Market: Distribution Movement Analysis
                    9.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
                    9.4. Retail Pharmacies
                        9.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
                    9.5. Hospital Pharmacies
                        9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    9.6. Online Pharmacies
                        9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
                    10.1. Recent Developments & Impact Analysis, By Key Market Participants
                    10.2. Company/Competition Categorization
                    10.3. Vendor Landscape
                        10.3.1. Key company heat map analysis, 2024
                    10.4. Company Profiles
                        10.4.1. Melinta Therapeutics
                            10.4.1.1. Company overview
                            10.4.1.2. Financial performance
                            10.4.1.3. Product benchmarking
                            10.4.1.4. Strategic initiatives
                        10.4.2. Merck & Co., Inc.
                            10.4.2.1. Company overview
                            10.4.2.2. Financial performance
                            10.4.2.3. Product benchmarking
                            10.4.2.4. Strategic initiatives
                        10.4.3. Melinta Therapeutics LLC
                            10.4.3.1. Company overview
                            10.4.3.2. Financial performance
                            10.4.3.3. Product benchmarking
                            10.4.3.4. Strategic initiatives
                        10.4.4. Theravance Biopharma.
                            10.4.4.1. Company overview
                            10.4.4.2. Financial performance
                            10.4.4.3. Product benchmarking
                            10.4.4.4. Strategic initiatives
                        10.4.5. Paratek Pharmaceuticals, Inc.
                            10.4.5.1. Company overview
                            10.4.5.2. Financial performance
                            10.4.5.3. Product benchmarking
                            10.4.5.4. Strategic initiatives
                        10.4.6. Seres Therapeutics
                            10.4.6.1. Company overview
                            10.4.6.2. Financial performance
                            10.4.6.3. Product benchmarking
                            10.4.6.4. Strategic initiatives
                        10.4.7. AbbVie Inc.
                            10.4.7.1. Company overview
                            10.4.7.2. Financial performance
                            10.4.7.3. Product benchmarking
                            10.4.7.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 U.S. Antibiotic Resistance market, by Disease, 2018 - 2030 (USD Million)
Table 3 U.S. Antibiotic Resistance market, by Pathogen, 2018 - 2030 (USD Million)
Table 4 U.S. Antibiotic Resistance market, by Drug Class, 2018 - 2030 (USD Million)
Table 5 U.S. Antibiotic Resistance market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 6 U.S. Antibiotic Resistance market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. antibiotic resistance market: market outlook
Fig. 10 U.S. antibiotic resistance competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. antibiotic resistance market driver impact
Fig. 16 U.S. antibiotic resistance market restraint impact
Fig. 17 U.S. antibiotic resistance market strategic initiatives analysis
Fig. 18 U.S. antibiotic resistance market: Disease movement analysis
Fig. 19 U.S. antibiotic resistance market: Disease outlook and key takeaways
Fig. 20 cUTI market estimates and forecast, 2018 - 2030
Fig. 21 CDI estimates and forecast, 2018 - 2030
Fig. 22 ABSSSI market estimates and forecast, 2018 - 2030
Fig. 23 HABP market estimates and forecast, 2018 - 2030
Fig. 24 CABP market estimates and forecast, 2018 - 2030
Fig. 25 cIAI estimates and forecast, 2018 - 2030
Fig. 26 BSI estimates and forecast, 2018 - 2030
Fig. 27 U.S. antibiotic resistance market: Pathogen movement analysis
Fig. 28 U.S. antibiotic resistance market: Pathogen outlook and key takeaways
Fig. 29 E. coli market estimates and forecasts, 2018 - 2030
Fig. 30 klebsiella pneumoniae market estimates and forecasts, 2018 - 2030
Fig. 31 P. aeruginosa market estimates and forecasts, 2018 - 2030
Fig. 32 S. aureus market estimates and forecasts, 2018 - 2030
Fig. 33 A. baumannii market estimates and forecasts, 2018 - 2030
Fig. 34 Strep. Pneumoniae market estimates and forecasts, 2018 - 2030
Fig. 35 H. influenzae market estimates and forecasts, 2018 - 2030
Fig. 36 CDI market estimates and forecasts, 2018 - 2030
Fig. 37 Enterococcus fecium market estimates and forecasts, 2018 - 2030
Fig. 38 U.S. antibiotic resistance market: Drug class movement analysis
Fig. 39 U.S. antibiotic resistance market: Drug class outlook and key takeaways
Fig. 40 Oxazolidinones market estimates and forecasts, 2018 - 2030
Fig. 41 Lipoglycopeptides market estimates and forecasts, 2018 - 2030
Fig. 42 Tetracyclines market estimates and forecasts, 2018 - 2030
Fig. 43 Combination therapies market estimates and forecasts, 2018 - 2030
Fig. 44 Cephalosporins market estimates and forecasts, 2018 - 2030
Fig. 45 Others market estimates and forecasts, 2018 - 2030
Fig. 46 U.S. antibiotic resistance market: Mechanism of action movement analysis
Fig. 47 U.S. antibiotic resistance market: Mechanism of action outlook and key takeaways
Fig. 48 Protein synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 49 Cell wall synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 50 RNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 51 DNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 52 Others market estimates and forecasts, 2018 - 2030
Fig. 53 U.S. antibiotic resistance market: Distribution channel movement analysis
Fig. 54 U.S. antibiotic resistance market: Distribution channel outlook and key takeaways
Fig. 55 Retail pharmacies market estimates and forecasts, 2018 - 2030
Fig. 56 Hospital pharmacies market estimates and forecasts, 2018 - 2030
Fig. 57 Online pharmacies market estimates and forecasts, 2018 - 2030